Thomas Weisel Keeps Outperform on Santarus

Analyst Donald Ellis sees upside, following news that the FDA approved an application for Rapinex powder

Thomas Weisel keeps the outperform rating on Santarus (SNTS ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.